Literature DB >> 2155718

Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery.

J M Wierda1, G F Karliczek, R H Vandenbrom, I Pinto, U W Kersten-Kleef, D K Meijer, S Agoston.   

Abstract

The haemodynamic effects of 200 micrograms.kg-1 pipecuronium and pancuronium were compared under etomidate/piritramide anaesthesia in 20 patients scheduled for elective coronary artery surgery. Following the completion of the haemodynamic measurements (ten minutes), anaesthesia was maintained by etomidate/sufentanil infusion. The mean changes in cardiac output were approximately -19 and -2 per cent and in heart rate -1 and +26 per cent for pipecuronium and pancuronium respectively. Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes). The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1. Approximately 56 per cent of the dose was recovered from the urine within 24 hours of administration and about 25 per cent of this was the metabolite, 3-desacetyl pipecuronium. High-dose pipecuronium administration under the anaesthetic regimen employed did not produce deleterious haemodynamic effects. The pharmacokinetic variables after bolus injection of pipecuronium did not deviate from those reported under normothermic conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155718     DOI: 10.1007/BF03005467

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  26 in total

1.  Pharmacokinetic analyses with RUGFIT: an interactive pharmacokinetic computer program.

Authors:  A H Scaf
Journal:  Biopharm Drug Dispos       Date:  1988 Sep-Oct       Impact factor: 1.627

Review 2.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

3.  Pharmacokinetics and disposition of pipecuronium bromide in the cat.

Authors:  S Agoston; R H Vandenbrom; J M Wierda; M C Houwertjes; U W Kersten
Journal:  Eur J Anaesthesiol       Date:  1988-07       Impact factor: 4.330

4.  Variations in pancuronium requirement, plasma concentration, and urinary excretion induced by cardiopulmonary bypass with hypothermia.

Authors:  A A d'Hollander; P Duvaldestin; D Henzel; M Nevelsteen; J P Bomblet
Journal:  Anesthesiology       Date:  1983-06       Impact factor: 7.892

5.  Clinical experience with a new steroid muscle relaxant: pipecurium bromide.

Authors:  A A Bunjatjan; V I Miheev
Journal:  Arzneimittelforschung       Date:  1980

6.  Adverse effects of pancuronium during high-dose fentanyl anesthesia for coronary artery bypass grafting.

Authors:  I R Thomson; C L Putnins
Journal:  Anesthesiology       Date:  1985-06       Impact factor: 7.892

7.  Pharmacological study of a new competitive neuromuscular blocking steroid, pipecurium bromide.

Authors:  E Kárpáti; K Biró
Journal:  Arzneimittelforschung       Date:  1980

8.  Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans.

Authors:  E Tassonyi; G Szabó; L Vereczkey
Journal:  Arzneimittelforschung       Date:  1981

9.  Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat.

Authors:  R D Miller; S Agoston; F van der Pol; L H Booij; J F Crul; J Ham
Journal:  J Pharmacol Exp Ther       Date:  1978-11       Impact factor: 4.030

10.  Cardiovascular effects of non-depolarizing neuromuscular blockers in patients with coronary artery disease.

Authors:  D H Sethna; N J Starr; F G Estafanous
Journal:  Can Anaesth Soc J       Date:  1986-05
View more
  9 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  The safe use of anaesthetics and muscle relaxants in older surgical patients.

Authors:  P M Lauven; J Nadstawek; S Albrecht
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

Review 4.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 5.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 6.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 7.  The use of muscle relaxants in the intensive care unit.

Authors:  M D Sharpe
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

8.  A comparison of pipecuronium with pancuronium on haemodynamic variables and plasma catecholamines in coronary artery bypass patients.

Authors:  P P Neidhart; P Champion; J Vogel; E K Zsigmond; E Tassonyi
Journal:  Can J Anaesth       Date:  1994-06       Impact factor: 5.063

Review 9.  New developments in nondepolarizing muscle relaxants.

Authors:  R K Mirakhur
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.